Robert Press, MD
Infectious Disease · New York, NYNPI 1538217195
Payments from drug & device makers
Across 19 payments — averaging $119.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shionogi Inc$1K
- AbbVie$231
- Bioxcel Therapeutics, Inc.$229
- Ferring Pharmaceuticals Inc.$158
- Novocure Inc.$139
- Theratechnologies Inc.$107
- plus $96 from 3 others
What the payments were for
- Consulting fees$1,20053%
- Food & beverage$1,07947%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shionogi Inc | 2 | $1,320 |
| AbbVie | 8 | $231 |
| Bioxcel Therapeutics, Inc. | 2 | $229 |
| Ferring Pharmaceuticals Inc. | 2 | $158 |
| Novocure Inc. | 1 | $139 |
| Theratechnologies Inc. | 1 | $107 |
| Cormedix Inc. | 1 | $65 |
| Hologic Sales And Service, LLC | 1 | $16 |
| Myovant Sciences Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,279 in reported general payments places this provider in the 70th percentile of 799 infectious disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 23 | $88,498 |
| Atorvastatin Calcium | 42 | $1,055 |
| Chlorthalidone | 15 | $333 |
| Metoprolol Succinate | 15 | $279 |
| Lorazepam | 12 | $155 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 14 | $105 |
| Zolpidem Tartrate | 11 | $65 |
| Meloxicam | 13 | $58 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in New York
- Wafaa El SadrNew York$119.1M
- Judith AbergNew York$14.8M
- Magdalena SobieszczykNew York$2.9M
- Kristen MarksNew York$2.8M
- Genovefa PapanicolaouNew York$2.7M
- Thomas WalshNew York$1.4M
- Sean LiuNew York$1.4M
- Martin MarkowitzNew York$1.4M
- Angelica KottkampNew York$1.2M
- Michelle CespedesNew York$819K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.